Sun US Chief Settles Insider Trading Case

Top Sun Pharma executive Abhay Gandhi and his wife have settled a case pertaining to alleged insider trading in shares of Ranbaxy around the time of the company’s acquisition by Sun from Daiichi Sankyo in 2014. Sun, which has been firefighting a raft of governance concerns, has vouched for the executive’s integrity.

Graph — SUN'S NORTH AMERICA CEO SETTLES INSIDER TRADING CASE IN INDIA • Source: Shutterstock

Insider trading allegations pertaining to the acquisition of Ranbaxy Laboratories Ltd. have haunted Sun Pharmaceutical Industries Ltd. in the past, and a top Sun executive and his spouse have now settled one such case with the Securities and Exchange Board of India (SEBI).

Abhay Gandhi, currently Sun’s CEO (North America), and his wife Kiran have now settled with the Indian markets regulator a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

27 Jun 2025

• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.